Comparative Effectiveness of Tirzepatide vs GLP-1 Agonists on VTE Risk in Obesity

A real-world cohort study comparing the risk of venous thromboembolism between patients with obesity initiating tirzepatide versus GLP-1 receptor agonists. The dataset likely contains results from a propensity score-matched analysis of 701,374 patients from the TriNetX network between January 2022 and August 2025. It was authored by Jheng-Yan Wu and shared under a CC-BY-4.0 license.

Use Cases

• Compare 1-year incidence rates of venous thromboembolism between two drug classes based on hazard ratios.
• Analyze the differential impact on pulmonary embolism versus deep vein thrombosis outcomes.
• Assess the association between medication initiation and all-cause mortality in a real-world population.
• Evaluate residual confounding in observational studies using negative control outcomes and E-values.

Strengths

• Large matched cohort of 701,374 patients derived from a global federated health research network.
• Study design includes propensity score matching to balance baseline demographics, comorbidities, and laboratory parameters.
• Results include hazard ratios with 95% confidence intervals for primary and secondary outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The observational nature of the study means causality cannot be established, as noted in the conclusion.

Provenance

Source

TriNetX global federated health research network.

Collection Method

Retrospective cohort study using an active-comparator, new-user design.

Time Range

January 2022 to August 2025.

Freshness

Last updated 2026-05-19 05:28:29; freshness should be verified.